- Trials with a EudraCT protocol (23)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
23 result(s) found for: Blue light.
Displaying page 1 of 2.
EudraCT Number: 2013-000634-35 | Sponsor Protocol Number: CB-17-01/08 | Start Date*: 2013-05-11 | |||||||||||
Sponsor Name:Cosmo Technologies Ltd. | |||||||||||||
Full Title: Effect of oral administration of Methylene Blue MMX® tablets on double-stranded DNA damage assessed by γH2AX analysis of colon biopsy samples | |||||||||||||
Medical condition: Out-patients of both sexes scheduled for a screening or surveillance colonoscopy and identified as having the clinical requirement for a second colonoscopy within 2 weeks of the initial colonoscopy. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-005403-17 | Sponsor Protocol Number: KH-MS-JAW-01 | Start Date*: 2007-12-10 | ||||||||||||||||
Sponsor Name:GE Healthcare | ||||||||||||||||||
Full Title: A prospective, comparative single center study of Hexvix® fluorescence uretero-renoscopy and white light uretero-renoscopy in the detection of upper urinary tract urothelial cell carcinoma | ||||||||||||||||||
Medical condition: Upper urinary tract (ureters and pyela/renal pelvises) urothelial cell carcinoma for which blue light uretero-renoscopy and biopsies are performed for diagnosis. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-003983-32 | Sponsor Protocol Number: CB-17-01/06 | Start Date*: 2013-10-02 |
Sponsor Name:Cosmo Technologies Ltd | ||
Full Title: The safety and efficacy of Methylene Blue MMX® modified release tablets administered to subjects undergoing screening or surveillance colonoscopy. | ||
Medical condition: Polyp and adenoma detection during colonoscopy | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IT (Completed) BE (Completed) DE (Completed) NL (Ongoing) LT (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2011-004269-34 | Sponsor Protocol Number: PCB202/11 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Photocure ASA | |||||||||||||
Full Title: An open, prospective, within-patient, controlled, multi-center phase IIa study of Hexvix flexible fluorescence cystoscopy and white light flexible cystoscopy in the detection of bladder cancer afte... | |||||||||||||
Medical condition: The patients should be indicated for a transurethral resection of the bladder (TURB) based on an outpatient cystoscopy and fulfil the following inclusion criteria: • Patients with multiple bladder... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-001819-30 | Sponsor Protocol Number: Sano2011 | Start Date*: 2011-10-18 | |||||||||||
Sponsor Name:Sanochemia Pharmazeutika AG | |||||||||||||
Full Title: Detection of non-muscle invasive bladder cancer using PVP-Hypericin (Vidon®) fluorescence cystoscopy (Hypericin PDD) | |||||||||||||
Medical condition: Suspected non-muscle invasive (superficial) bladder cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-002760-16 | Sponsor Protocol Number: 04/QO603/42 HEXVIX | Start Date*: 2005-01-12 | |||||||||||
Sponsor Name:Guy's and St Thomas' NHS Foundation Trust | |||||||||||||
Full Title: A randomised Study of “bluelight” hexyl amino levulinic acid (HAL) photodynamic assisted resection of bladder tumours versus conventional “white light” transurethral resection of newly diagnosed bl... | |||||||||||||
Medical condition: Superficial Bladder Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-000559-15 | Sponsor Protocol Number: FB2012 | Start Date*: 2012-09-14 |
Sponsor Name:FinnBladder | ||
Full Title: TREATMENT OF Ta BLADDER CANCER WITH HIGH RISK OF RECURRENCE – FLUORESCENCE CYSTOSCOPY WITH OPTIMIZED ADJUVANT MITOMYCIN-C | ||
Medical condition: bladder cancer (non-invasive Ta urothelial bladder cancer) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FI (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-002422-23 | Sponsor Protocol Number: twostepala | Start Date*: 2019-01-08 | |||||||||||
Sponsor Name:Akershus University Hospital | |||||||||||||
Full Title: Extracorporeal photopheresis of patients with Crohns disease using 5- aminolevulinic acid. | |||||||||||||
Medical condition: Crohns disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NO (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-004074-93 | Sponsor Protocol Number: EP005 | Start Date*: 2005-03-01 |
Sponsor Name:EpiTan Limited | ||
Full Title: A Pilot, Phase II, Open, Controlled Study to Evaluate the Safety, Tolerability and Efficacy of a Subcutaneous Implant of Melanotan in Patients Suffering from Recurrent Polymorphous Light Eruption. | ||
Medical condition: Polymorphous Light Eruption (PMLE) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FI (Completed) DK (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2006-003391-35 | Sponsor Protocol Number: LT1910-PIV-01/06 (NL) | Start Date*: 2006-09-13 | |||||||||||
Sponsor Name:Laboratoires THEA | |||||||||||||
Full Title: Evaluation of the efficacy and safety of unpreserved dexamethasone phosphate 0.1% eye drops (T1910) versus placebo in patients with bilateral treated severe keratoconjunctivitis sicca due to Sjögre... | |||||||||||||
Medical condition: keratoconjunctivitis sicca | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-005017-12 | Sponsor Protocol Number: EyeADHD-01 | Start Date*: 2014-03-31 | |||||||||||
Sponsor Name:Parnassia Bavo Groep - PsyQ | |||||||||||||
Full Title: Looking into the eye of ADHD. Investigating the relationship between ADHD, the delayed circadian rhythm and the functioning of the eye. | |||||||||||||
Medical condition: Adults with ADHD and suboptimal eye functioning. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-002644-23 | Sponsor Protocol Number: MB_PDT_1 | Start Date*: 2020-07-23 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Dept. of Dermatology, Zealand University Hospital, Roskilde | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: Photodynamic therapy of antifungal resistant dermatophytes | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Competent patients over 18 years old with mycological verified antifungal resistant dermatophytosis | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: DK (Prematurely Ended) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-003932-38 | Sponsor Protocol Number: 50797 | Start Date*: 2016-03-30 | |||||||||||
Sponsor Name:VU University medical center (VUmc) | |||||||||||||
Full Title: Advanced imaging in laparoscopic HIPEC for peritoneal carcinomatosis of colorectal orgin to improve cytoreduction; a feasibility study | |||||||||||||
Medical condition: Peritoneal carcinomatosis from colorectal origin | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-003500-40 | Sponsor Protocol Number: PQ-110-002 | Start Date*: 2019-04-08 | |||||||||||
Sponsor Name:ProQR Therapeutics IV B.V. | |||||||||||||
Full Title: An Open-Label Extension Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of QR-110 in Subjects with Leber Congenital Amaurosis (LCA) due to the C.2991+1655a>G Mutation (P.... | |||||||||||||
Medical condition: Leber Congenital Amaurosis (LCA) due to c.2991+1655A>G Mutation (p.Cys998X) in the CEP290 Gene | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-002465-35 | Sponsor Protocol Number: B3461028 | Start Date*: 2014-04-07 | |||||||||||
Sponsor Name:FoldRx Pharmaceuticals, a Pfizer Company | |||||||||||||
Full Title: A multicentre, international, phase 3, double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety and tolerability of daily oral dosing of tafamidis meglumine (PF-06291826)... | |||||||||||||
Medical condition: Transthyretin amyloid cardiomyopathy (TTR-CM) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) IT (Completed) ES (Completed) DE (Completed) SE (Completed) CZ (Completed) NL (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-000535-45 | Sponsor Protocol Number: PQ-110-005 | Start Date*: 2020-11-13 | |||||||||||
Sponsor Name:ProQR Therapeutics IV B.V. | |||||||||||||
Full Title: An Open-Label, Dose Escalation and Double-Masked, Randomized, Controlled Study to Evaluate the Safety and Tolerability of Sepofarsen in Pediatric Subjects <8 Years of Age with Leber Congenital Amau... | |||||||||||||
Medical condition: Leber Congenital Amaurosis 10 (LCA10) due to c.2991+1655A>G mutation (p.Cys998X) in the CEP290 Gene | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) DE (Completed) GB (GB - no longer in EU/EEA) NL (Ongoing) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-003501-25 | Sponsor Protocol Number: PQ-110-003 | Start Date*: 2019-02-28 | |||||||||||
Sponsor Name:ProQR Therapeutics IV B.V. | |||||||||||||
Full Title: A Double-Masked, Randomized, Controlled, Multiple-Dose Study to Evaluate the Efficacy, Safety, Tolerability and Systemic Exposure of QR-110 in Subjects with Leber’s Congenital Amaurosis (LCA) due t... | |||||||||||||
Medical condition: Leber’s Congenital Amaurosis (LCA) due to c.2991+1655A>G Mutation (p.Cys998X) in the CEP290 Gene | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) NL (Ongoing) BE (Completed) FR (Ongoing) GB (GB - no longer in EU/EEA) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-004981-16 | Sponsor Protocol Number: 1991-201-008 | Start Date*: 2022-06-17 | |||||||||||
Sponsor Name:Editas Medicine, Inc. | |||||||||||||
Full Title: Open-Label, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Efficacy of EDIT-101 in Adult and Pediatric Participants with Leber Congenital Amaurosis Type 10 (LCA10), with Cen... | |||||||||||||
Medical condition: Leber Congenital Amaurosis Type 10 (LCA10), with Centrosomal Protein 290 (CEP290)-Related Retinal Degeneration Caused by a Compound Heterozygous or Homozygous Mutation Involving c.2991+1655A>G in I... | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-002987-14 | Sponsor Protocol Number: BN40423 | Start Date*: 2019-02-13 | |||||||||||
Sponsor Name:F.Hoffmann La-Roche Ltd | |||||||||||||
Full Title: A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE III CLINICAL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INTRATHECALLY ADMINISTERED RO7234292 (RG6042) IN PATIENTS WITH MANIFEST ... | |||||||||||||
Medical condition: Huntington's disease (HD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DK (Completed) NL (Completed) AT (Completed) PL (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-004108-23 | Sponsor Protocol Number: 17097AB-AS | Start Date*: 2018-10-09 |
Sponsor Name:Belfast Health and Social Care Trust | ||
Full Title: Low-dose atropine eye drops to reduce progression of myopia in children: a multi-centre placebo controlled randomised trial in the United Kingdom (CHAMP UK) | ||
Medical condition: Myopia | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
